Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

95.22
-0.4950-0.52%
Pre-market: 95.21-0.0050-0.01%04:35 EDT
Volume:737.18K
Turnover:70.75M
Market Cap:6.56B
PE:-30.55
High:97.37
Open:96.67
Low:95.10
Close:95.71
52wk High:122.20
52wk Low:74.50
Shares:68.85M
Float Shares:65.39M
Volume Ratio:0.92
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1172
EPS(LYR):-3.1100
ROE:-117.04%
ROA:-30.96%
PB:63.66
PE(LYR):-30.62

Loading ...

Health Canada Approves Rhythm Pharma’s Imcivree for Acquired Hypothalamic Obesity Weight Management

Reuters
·
Sep 22

Rhythm Pharmaceuticals Announces Health Canada Approval of Imcivree® (Setmelanotide) for Weight Management in Adult and Pediatric Patients 4 Years of Age and Older with Acquired Hypothalamic Obesity

THOMSON REUTERS
·
Sep 22

Wolfe Research Initiates Rhythm Pharmaceuticals at Outperform

MT Newswires Live
·
Sep 17

Rhythm Pharmaceuticals initiated with an Outperform at Wolfe Research

TIPRANKS
·
Sep 17

S&P 500 Futures Climb in Premarket Trading; Brookfield Infrastructure, Avnet Lead

Dow Jones
·
Sep 16

RBC Capital Reaffirms Their Buy Rating on Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Sep 15

Rhythm Pharmaceuticals Coverage Assumed by Leerink Partners at Outperform

Dow Jones
·
Sep 15

Rhythm Pharmaceuticals assumed with an Outperform at Leerink

TIPRANKS
·
Sep 14

Rhythm Pharmaceuticals Highlights Imcivree Launch Progress in Acquired Hypothalamic Obesity Presentation

Reuters
·
Sep 09

Rhythm Pharma CFO Hunter C. Smith Disposes of Common Shares Worth $6.61 Million

Reuters
·
Sep 02

Will Japan’s First IMCIVREE Approval in Hypothalamic Obesity Change Rhythm Pharmaceuticals’ (RYTM) Narrative

Simply Wall St.
·
Aug 31

Rhythm Pharmaceuticals Initiated at Hold by Deutsche Bank

Dow Jones
·
Aug 28

Rhythm Pharmaceuticals, Inc. : Deutsche Bank Initiates Coverage with Hold Rating and Target Price $120

THOMSON REUTERS
·
Aug 28

Rhythm Pharmaceuticals initiated with a Hold at Deutsche Bank

TIPRANKS
·
Aug 28

Rhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued As Japan Approval Lifts Its Story

Simply Wall St.
·
Aug 26

Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Aug 25

Rhythm Pharma Says Japan Regulator Approves Imcivree for Acquired Hypothalamic Obesity

Reuters
·
Aug 24

Rhythm Pharmaceuticals, - Imcivree Launch in Japan Expected by End of 2026 Pending Pricing

THOMSON REUTERS
·
Aug 24

How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Expanded UK Approval For IMCIVREE In Hypothalamic Obesity

Simply Wall St.
·
Aug 22

Rhythm Pharma Files Form 3 for Chief Medical Officer Manher Joshi

Reuters
·
Aug 19